ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001

Also written as “ISB 2001” and “ABBV-2001”.

In AbbVie’s pipeline, BCMA, CD38, CD3. Its studies are mostly in Multiple Myeloma, led by 2 companies.

Furthest: phase 2, since Mar 19, 20252 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only11 open or runningphase 2since Mar 19, 2025Mar 19, 2025Dec 2035phase 2 · NCT06892522
Ichnos Sciencesits history only11 open or runningphase 1since May 4, 2023May 4, 2023Jul 2027phase 1 · NCT05862012
  • Named in AbbVie’s own pipeline as ABBV-2001 (ISB 2001), phase 1, as of Jul 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2023First study: phase 1 study in Multiple MyelomaNew to Ichnos SciencesIchnos Sciences · NCT05862012 · 200 planned · United States, Australia, France and more
  2. Mar 19, 2025AbbVie’s first study: phase 2 study in Multiple MyelomaNew to AbbVieAbbVie · NCT06892522 · 602 planned · United States, Australia, Israel and more

Ahead

  1. Jul 2027Primary completion: phase 1 study in Multiple MyelomaIchnos Sciences · NCT05862012
  2. Dec 2035Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT06892522

TargetBeta

“BCMA, CD38, CD3”the company's pipeline, read by Claude · source
“A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) CD38 and human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), and the T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06892522Multiple Myeloma · United States, Australia, Israel and more2RecruitingAbbVieDec 2035602
NCT05862012Multiple Myeloma · United States, Australia, France and more1RecruitingIchnos SciencesJul 2027200

How it is read

Names in the registry

  • “ISB 2001”, 2 entries
  • “ABBV-2001”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.